IDEX 10-Q 2026-09-30
IEX · CIK 832101 · Form 10-Q · Period ended September 30, 2026 · Filed October 28, 2026
Revenue rose 8.3% to $952 million. Operating margin was 21.9%, against 21.1% a year earlier. Net income was $144 million.
8 sections, 191K characters. Original on sec.gov · ·
| Measure | Quarter ended Sep 30, 2026 | Quarter ended Sep 30, 2025 | Change |
|---|---|---|---|
| Revenue | $952M | $879M | +8.3% |
| Operating income | $208M | $186M | +11.9% |
| Net income | $144M | $128M | +12.8% |
| Diluted EPS | $1.95 | $1.70 | +14.7% |
| Cash and equivalents | $602M | n/a | n/a |
| Operating margin* | 21.9% | 21.1% | +0.7 pts |
From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.
Cover and table of contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
| ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||||
| For the quarterly period ended | September 30, 2026 |
OR
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||||
| For the transition period | from _____to _____ |
Commission File Number: 1-10235
IDEX CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 36-3555336 | |||||||||||||||||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||||||||||||||
| 3100 Sanders Road, | Suite 301, | Northbrook, | Illinois | 60062 | ||||||||||||||||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (847) 498-7070
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Common Stock, par value $0.01 per share | IEX | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☑ | Accelerated filer ☐ | Non-accelerated filer ☐ | Smaller reporting company | ☐ | |||||||||||||||||||||
| Emerging growth company | ☐ | |||||||||||||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☑
Number of shares of common stock of IDEX Corporation outstanding as of October 23, 2026: 73,452,801.
TABLE OF CONTENTS
Cautionary Statement Under the Private Securities Litigation Reform Act
This quarterly report on Form 10-Q, including the “Overview,” “Results of Operations” and “Liquidity and Capital Resources” sections of this Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company’s business strategy, outlook and the assumptions underlying these expectations, capital return strategy, plant and equipment capacity for future growth, other high-growth opportunities, planned production, anticipated future acquisition behavior, resource and capital deployment and focus on organic and inorganic growth, the Company’s ability to adapt to macroeconomic challenges and anticipated adaptability of resource deployment, anticipated impacts of tariffs, tariff refunds and global trade policies and changes in law, the Company’s future market positioning, anticipated trends in end markets, including expectations regarding market sector contraction, recovery, stabilization or growth and underlying drivers of such expectations, expectations regarding future order volumes and order patterns, demand within end markets, availability and sufficiency of cash and financing alternatives, the impacts of any pending or threatened legal, regulatory and other proceedings involving the Company and its subsidiaries, anticipated benefits and restructuring charges, including severance charges, related to the Company’s organizational changes, the anticipated tax treatment of the Company’s recent acquisitions, the expected contingent consideration payable related to the Company’s recent acquisitions, the anticipated benefits and performance of the Company’s recent or future acquisitions, anticipated growth initiatives and expansions and execution of those growth initiatives and the anticipated benefits of the Company’s productivity and cost containment efforts, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “guidance,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “likely to be,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this report.
The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries; the impact of severe weather events, natural disasters and public health threats; economic and political consequences resulting from terrorist attacks, wars and global conflicts; the Company’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; cybersecurity incidents; the continued growth of artificial intelligence (“AI”) and any related changes to demand in AI-driven markets served by the Company’s customers; the relationship of the U.S. Dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in countries in which the Company operates; developments with respect to trade policy and existing, new or increased tariffs or other similar measures; changes to applicable laws and regulations, including tax laws; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters.
Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company’s subsequent quarterly reports filed with the United States Securities and Exchange Commission (“SEC”) and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this report, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per share amounts)
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net sales | $ | 951.7 | $ | 878.7 | $ | 2,759.2 | $ | 2,558.4 | |||||||||||||||
| Cost of sales | 522.2 | 488.1 | 1,504.8 | 1,406.7 | |||||||||||||||||||
| Gross profit | 429.5 | 390.6 | 1,254.4 | 1,151.7 | |||||||||||||||||||
| Selling, general and administrative expenses | 218.1 | 204.7 | 660.5 | 617.7 | |||||||||||||||||||
| Restructuring expenses and asset impairments | 3.4 | 0.1 | 13.6 | 18.3 | |||||||||||||||||||
| Operating income | 208.0 | 185.8 | 580.3 | 515.7 | |||||||||||||||||||
| Other (income) expense – net | (0.1) | (1.2) | (2.0) | 2.6 | |||||||||||||||||||
| Interest expense – net | 15.4 | 16.5 | 46.5 | 48.2 | |||||||||||||||||||
| Income before income taxes | 192.7 | 170.5 | 535.8 | 464.9 | |||||||||||||||||||
| Provision for income taxes | 48.7 | 42.8 | 128.5 | 110.7 | |||||||||||||||||||
| Net income | 144.0 | 127.7 | 407.3 | 354.2 | |||||||||||||||||||
| Net loss attributable to noncontrolling interest | 0.1 | 0.1 | 0.2 | 0.7 | |||||||||||||||||||
| Net income attributable to IDEX | $ | 144.1 | $ | 127.8 | $ | 407.5 | $ | 354.9 | |||||||||||||||
| Earnings per common share: | |||||||||||||||||||||||
| Basic earnings per common share attributable to IDEX | $ | 1.95 | $ | 1.70 | $ | 5.50 | $ | 4.70 | |||||||||||||||
| Diluted earnings per common share attributable to IDEX | $ | 1.95 | $ | 1.70 | $ | 5.49 | $ | 4.70 | |||||||||||||||
| Share data: | |||||||||||||||||||||||
| Basic weighted average common shares outstanding | 73.7 | 75.1 | 74.0 | 75.4 | |||||||||||||||||||
| Diluted weighted average common shares outstanding | 74.0 | 75.2 | 74.2 | 75.5 |
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net income | $ | 144.0 | $ | 127.7 | $ | 407.3 | $ | 354.2 | |||||||||||||||
| Other comprehensive (loss) income: | |||||||||||||||||||||||
| Pension and other postretirement adjustments, net of tax | (0.2) | (0.1) | (0.5) | (0.5) | |||||||||||||||||||
| Cumulative translation adjustment | (16.7) | (2.8) | (72.4) | 176.7 | |||||||||||||||||||
| Other comprehensive (loss) income, net of tax | (16.9) | (2.9) | (72.9) | 176.2 | |||||||||||||||||||
| Comprehensive income | 127.1 | 124.8 | 334.4 | 530.4 | |||||||||||||||||||
| Comprehensive loss attributable to noncontrolling interest | 0.1 | 0.1 | 0.2 | 0.7 | |||||||||||||||||||
| Comprehensive income attributable to IDEX | $ | 127.2 | $ | 124.9 | $ | 334.6 | $ | 531.1 |
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per share amounts)
(unaudited)
| September 30, 2026 | December 31, 2025 | ||||||||||
| ASSETS | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 602.1 | $ | 580.0 | |||||||
| Receivables – net | 548.6 | 521.7 | |||||||||
| Inventories – net | 529.1 | 479.4 | |||||||||
| Other current assets | 86.7 | 62.1 | |||||||||
| Total current assets | 1,766.5 | 1,643.2 | |||||||||
| Property, plant and equipment – net of accumulated depreciation of $702.9 and $654.3 at September 30, 2026 and December 31, 2025, respectively | 466.9 | 468.0 | |||||||||
| Goodwill | 3,371.9 | 3,414.5 | |||||||||
| Intangible assets – net | 1,129.0 | 1,247.4 | |||||||||
| Other noncurrent assets | 144.5 | 153.9 | |||||||||
| Total assets | $ | 6,878.8 | $ | 6,927.0 | |||||||
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities | |||||||||||
| Trade accounts payable | $ | 238.3 | $ | 224.7 | |||||||
| Accrued expenses | 343.4 | 297.0 | |||||||||
| Current portion of long-term borrowings | 0.4 | 0.7 | |||||||||
| Dividends payable | 53.8 | 53.0 | |||||||||
| Total current liabilities | 635.9 | 575.4 | |||||||||
| Long-term borrowings – net | 1,751.1 | 1,820.1 | |||||||||
| Deferred income taxes | 296.1 | 303.0 | |||||||||
| Other noncurrent liabilities | 180.7 | 202.3 | |||||||||
| Total liabilities | 2,863.8 | 2,900.8 | |||||||||
| Commitments and contingencies (Note 14) | |||||||||||
| Shareholders’ equity | |||||||||||
| Preferred stock: | |||||||||||
| Authorized: 5.0 million shares, $0.01 per share par value; Issued: None | — | — | |||||||||
| Common stock: | |||||||||||
| Authorized: 150.0 million shares, $0.01 per share par value | |||||||||||
| Issued: 90.1 million shares at both September 30, 2026 and December 31, 2025 | 0.9 | 0.9 | |||||||||
| Treasury stock at cost: 16.4 million shares at September 30, 2026 and 15.5 million shares at December 31, 2025 | (1,596.5) | (1,423.2) | |||||||||
| Additional paid-in capital | 881.7 | 892.1 | |||||||||
| Retained earnings | 4,745.7 | 4,500.1 | |||||||||
| Accumulated other comprehensive (loss) income | (15.3) | 57.6 | |||||||||
| Total shareholders’ equity | 4,016.5 | 4,027.5 | |||||||||
| Noncontrolling interest |
Showing the first 8K of 110K characters. Open the full section
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and related notes in this quarterly report. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under Item 1A, “Risk Factors” in the Company’s most recent annual report on Form 10-K and under the heading “Cautionary Statement Under the Private Securities Litigation Reform Act” discussed elsewhere in this quarterly report.
This discussion includes certain non-GAAP financial measures that have been defined and reconciled to the most directly comparable financial measure prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) under the headings “Non-GAAP Disclosures” and “Free Cash Flow.” This discussion also includes Operating working capital, which has been defined under the heading “Liquidity and Capital Resources.” The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.
Overview
IDEX is an applied solutions provider specializing in the manufacturing of health and science technologies, fluid and metering technologies, and fire, safety and other diversified products built to customers’ specifications. IDEX’s products are sold in niche markets across a wide range of industries throughout the world. Accordingly, IDEX’s businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where it does business, as well as by the relationship of the U.S. Dollar to other currencies. Levels of capacity utilization and capital spending in certain markets and overall industrial activity are important factors that influence the demand for IDEX’s products.
Highlights
(All comparisons are against the same period in 2025 unless otherwise noted)
Three Months Ended September 30, 2026
-
Net sales of $951.7 million increased 8% on both a reported basis and organically*
-
Reported diluted earnings per common share (“EPS”) attributable to IDEX of $1.95 increased 15%
-
Adjusted diluted EPS attributable to IDEX* of $2.33 increased 15%
-
Returned capital to shareholders in the form of $74.6 million of share repurchases and $54.0 million of dividends
*These are non-GAAP measures. See the definitions of these non-GAAP measures and reconciliations to their most directly comparable U.S. GAAP financial measures under the heading “Non-GAAP Disclosures.”
During the third quarter of 2026, the Company delivered strong results as continuous improvement efforts, the power of 8020, and measured pricing actions continued to expand margins while absorbing higher costs. Continued growth in targeted advantaged markets, including data centers, semiconductor and space and defense, primarily within the Health & Science Technologies (“HST”) segment, was complemented by broadening industrial strength across Fluid & Metering Technologies’ (“FMT”) and Fire & Safety/Diversified Products (“FSDP”).
Recent Developments
On February 20, 2026, the U.S. Supreme Court issued a decision invalidating the broad-based tariffs imposed under the International Emergency Economic Powers Act (“IEEPA”). The Company collected substantially all of the anticipated refunds of previously paid IEEPA tariffs during the second quarter of 2026 with minimal impact continuing into the third quarter of 2026.
The three months ended September 30, 2026 included a $0.7 million reduction of Cost of sales as well as a $1.6 million benefit to Net sales for revisions to estimated customer rebates, which together increased Gross margin by 10 basis points and contributed $0.02 to diluted EPS attributable to IDEX. The nine months ended September 30, 2026 included a $22.7 million reduction of Cost of sales as well as a $13.1 million reduction of Net sales from expected customer rebates associated with the refunds, which decreased organic sales growth by 1%, increased Gross margin 60 basis points and contributed $0.10 to diluted EPS attributable to IDEX during the nine months ended September 30, 2026.
In response to the U.S. Supreme Court ruling, the administration implemented new tariffs under alternative statutory authority and may continue implementing other additional tariffs. The tariffs enacted in 2025 and in the first quarter of 2026 did not have a material impact on the Company’s business or financial statements in the periods presented.
Results of Operations
The following is a discussion and analysis of the Company’s results of operations for the three and nine months ended September 30, 2026 compared with the three and nine months ended September 30, 2025.
| Three Months Ended September 30, | Change | Nine Months Ended September 30, | Change | ||||||||||||||||||||||||||||||||||||||||||||
| (In millions, except per share amounts) | 2026 | 2025 | $ | % / bps | 2026 | 2025 | $ | % / bps | |||||||||||||||||||||||||||||||||||||||
| Domestic sales | $ | 473.5 | $ | 459.2 | $ | 14.3 | 3 | % | $ | 1,397.7 | $ | 1,314.4 | $ | 83.3 | 6 | % | |||||||||||||||||||||||||||||||
| International sales | 478.2 | 419.5 | 58.7 | 14 | % | 1,361.5 | 1,244.0 | 117.5 | 9 | % | |||||||||||||||||||||||||||||||||||||
| Net sales | 951.7 | 878.7 | 73.0 | 8 | % | 2,759.2 | 2,558.4 | 200.8 | 8 | % | |||||||||||||||||||||||||||||||||||||
| Cost of sales | 522.2 | 488.1 | 34.1 | 7 | % | 1,504.8 | 1,406.7 | 98.1 | 7 | % | |||||||||||||||||||||||||||||||||||||
| Gross profit | 429.5 | 390.6 | 38.9 | 10 | % | 1,254.4 | 1,151.7 | 102.7 | 9 | % | |||||||||||||||||||||||||||||||||||||
| Gross margin | 45.1 | % | 44.5 | % | n/a | 60 bps | 45.5 | % | 45.0 | % | n/a | 50 bps | |||||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses | 218.1 | 204.7 | 13.4 | 7 | % | 660.5 | 617.7 | 42.8 | 7 | % | |||||||||||||||||||||||||||||||||||||
| Restructuring expenses and asset impairments | 3.4 | 0.1 | 3.3 | NM | 13.6 | 18.3 | (4.7) | (26 | %) | ||||||||||||||||||||||||||||||||||||||
| Operating income | 208.0 | 185.8 | 22.2 | 12 | % | 580.3 | 515.7 | 64.6 | 13 | % | |||||||||||||||||||||||||||||||||||||
| Other (income) expense – net | (0.1) | (1.2) | 1.1 | (92 | %) | (2.0) | 2.6 | (4.6) | (177 | %) | |||||||||||||||||||||||||||||||||||||
| Interest expense – net | 15.4 | 16.5 | (1.1) | (7 | %) | 46.5 | 48.2 | (1.7) | (4 | %) | |||||||||||||||||||||||||||||||||||||
| Income before income taxes | 192.7 | 170.5 | 22.2 | 13 | % | 535.8 | 464.9 | 70.9 | 15 | % | |||||||||||||||||||||||||||||||||||||
| Provision for income taxes | 48.7 | 42.8 | 5.9 | 14 | % | 128.5 | 110.7 | 17.8 | 16 | % | |||||||||||||||||||||||||||||||||||||
| Effective tax rate | 25.2 | % | 25.1 | % | n/a | 10 bps | 24.0 | % | 23.8 | % | n/a | 20 bps | |||||||||||||||||||||||||||||||||||
| Net income attributable to IDEX | $ | 144.1 | $ | 127.8 | $ | 16.3 | 13 | % | $ | 407.5 | $ | 354.9 | $ | 52.6 | 15 | % | |||||||||||||||||||||||||||||||
| Diluted earnings per common share attributable to IDEX | $ | 1.95 | $ | 1.70 | $ | 0.25 | 15 | % | $ | 5.49 | $ | 4.70 | $ | 0.79 | 17 | % | |||||||||||||||||||||||||||||||
Net Sales
Net sales for the three and nine months ended September 30, 2026 increased as compared to the same prior year periods primarily as a result of increased organic sales. Net sales for the nine months ended September 30, 2026 also reflect favorable impacts from foreign currency translation and contributions from acquisitions. Organic sales for the same periods increased 8% and 6%, respectively, driven by higher volumes, primarily in the HST segment. The increase in both periods also reflects positive price across all segments.
Gross Profit and Gross Margin
Gross profit and Gross margin for the three and nine months ended September 30, 2026 benefited from net operational productivity improvements and volume leverage. Mix benefited Gross profit and Gross margin for the three months ended September 30, 2026, but was unfavorable to Gross profit and Gross margin for the nine months ended September 30, 2026. Foreign currency translation favorably impacted Gross profit for the nine months ended September 30, 2026 with no impact to Gross margin. While Gross profit also benefited from favorable price/cost, cost increases were not fully recovered at historical margin rates, resulting in Gross margin pressure in both periods presented. Included in price/cost were the net benefits of IEEPA tariff refunds previously discussed.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased for the three and nine months ended September 30, 2026, reflecting a $1.9 million and $7.4 million increase from acquisitions, including amortization, respectively, as well as higher employee-related costs, including variable compensation, and increased professional services spending, partially offset by proceeds received related to legal settlements, as compared to the same prior year periods.
Restructuring Expenses and Asset Impairments
Restructuring expenses and asset impairments for the three months ended September 30, 2026 primarily relate to severance costs that were incurred as a result of employee reductions, including reductions in connection with the anticipated closure of a facility in the HST segment. The nine months ended September 30, 2026 also include asset impairments of $4.8 million related to intangible assets and property, plant and equipment within the Company’s FMT segment. Restructuring expenses and asset impairments for the three and nine months ended September 30, 2025 primarily relate to severance costs that were incurred in conjunction with organizational changes.
Other (Income) Expense – Net
Other (income) expense – net during the three and nine months ended September 30, 2026 and 2025 reflects the impact of foreign currency transactions.
Interest Expense – Net
Interest expense – net for the three months ended September 30, 2026 decreased primarily due to lower average borrowings under the Revolving Facility and higher interest income earned as compared to the prior year period. Interest expense – net for the nine months ended September 30, 2026 decreased primarily due to the payoff of the Company’s 3.37% Senior Notes in 2025.
Income Taxes
The effective tax rate was 25.2% and 24.0% for the three and nine months ended September 30, 2026, respectively, reasonably consistent with 25.1% and 23.8% during the respective same periods in 2025. For additional information, refer to Note 15, “Income Taxes,” in the Notes to Condensed Consolidated Financial Statements.
Results of Reportable Business Segments
The Company has three reportable segments: Health & Science Technologies (“HST”), Fluid & Metering Technologies (“FMT”) and Fire & Safety/Diversified Products (“FSDP”). For a detailed description of the operations within each segment, refer to Note 13, “Business Segments and Geographic Information,” in the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Management’s measurements of segment performance are Net sales, adjusted Earnings before interest, income taxes, depreciation and amortization (“Adjusted EBITDA”) and Adjusted EBITDA margin.
The table below illustrates the share of Net sales and Adjusted EBITDA contributed by each segment on the basis of total segments (not total Company) for the three and nine months ended September 30, 2026.
| Three Months Ended September 30, 2026 | Nine Months Ended September 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||
| HST | FMT | FSDP | Total | HST | FMT | FSDP | Total | ||||||||||||||||||||||||||||||||||||||||
| Net sales as a percent of total | 46 | % | 34 | % | 20 | % | 100 | % | 45 | % | 34 | % | 21 | % | 100 | % | |||||||||||||||||||||||||||||||
| Adjusted EBITDA(1) | 43 | % | 38 | % | 19 | % | 100 | % | 42 | % | 38 | % | 20 | % | 100 | % |
(1) Segment Adjusted EBITDA excludes the impact of unallocated corporate costs of $25.5 million and $81.8 million for the three and nine months ended September 30, 2026, respectively.
Health & Science Technologies Segment
| Three Months Ended September 30, | Components of Change | ||||||||||||||||||||||||||||||||||||||||
| (In millions) | 2026 | 2025 | Change | Organic | Acq/Div**(1)** | Foreign Currency | Total | ||||||||||||||||||||||||||||||||||
| Domestic sales | $ | 184.2 | $ | 184.1 | —% | ||||||||||||||||||||||||||||||||||||
| International sales | 249.3 | 196.9 | 27% | ||||||||||||||||||||||||||||||||||||||
| Net sales | $ | 433.5 | $ | 381.0 | 14% | 13% | 1% | —% | 14% | ||||||||||||||||||||||||||||||||
| Adjusted EBITDA | 124.8 | 105.4 | 18% | 20% | (1%) | (1%) | 18% | ||||||||||||||||||||||||||||||||||
| Adjusted EBITDA margin | 28.8 | % | 27.7 | % | 110 bps | 160 bps | (50) bps | — bps | 110 bps |
| Nine Months Ended September 30, | Components of Change | ||||||||||||||||||||||||||||||||||||||||
| (In millions) | 2026 | 2025 | Change | Organic | Acq/Div**(1)** | Foreign Currency | Total | ||||||||||||||||||||||||||||||||||
| Domestic sales | $ | 555.9 | $ | 505.5 | 10% | ||||||||||||||||||||||||||||||||||||
| International sales | 691.0 | 582.3 | 19% | ||||||||||||||||||||||||||||||||||||||
| Net sales | $ | 1,246.9 | $ | 1,087.8 | 15% | 12% | 2% | 1% | 15% | ||||||||||||||||||||||||||||||||
| Adjusted EBITDA | 350.1 | 287.8 | 22% | 21% | —% | 1% | 22% | ||||||||||||||||||||||||||||||||||
| Adjusted EBITDA margin | 28.1 | % | 26.5 | % | 160 bps | 210 bps | (50) bps | — bps | 160 bps |
(1) Acquisitions include Micro-LAM, Inc. (“Micro-LAM”) acquired in July 2025.
-
Organic sales for the three and nine months ended September 30, 2026 reflect higher volumes primarily due to AI-driven demand for data center power and semiconductor markets, as well as strength in space and defense and positive price.
-
Adjusted EBITDA margin for the three and nine months ended September 30, 2026 increased primarily due to volume leverage, partially offset by higher variable compensation and the impact of acquisitions. Additionally, favorable mix was offset by higher employee-related costs for the three months ended September 30, 2026.
Fluid & Metering Technologies Segment
| Three Months Ended September 30, | Components of Change | ||||||||||||||||||||||||||||||||||||||||
| (In millions) | 2026 | 2025 | Change | Organic | Acq/Div | Foreign Currency | Total | ||||||||||||||||||||||||||||||||||
| Domestic sales | $ | 186.4 | $ | 180.5 | 3% | ||||||||||||||||||||||||||||||||||||
| International sales | 141.5 | 136.6 | 4% | ||||||||||||||||||||||||||||||||||||||
| Net sales | $ | 327.9 | $ | 317.1 | 3% | 4% | —% | (1%) | 3% | ||||||||||||||||||||||||||||||||
| Adjusted EBITDA | 111.0 | 106.8 | 4% | 4% | —% | —% | 4% | ||||||||||||||||||||||||||||||||||
| Adjusted EBITDA margin | 33.9 | % | 33.7 | % | 20 bps | 20 bps | — bps | — bps | 20 bps |
| Nine Months Ended September 30, | Components of Change | ||||||||||||||||||||||||||||||||||||||||
| (In millions) | 2026 | 2025 | Change | Organic | Acq/Div | Foreign Currency | Total | ||||||||||||||||||||||||||||||||||
| Domestic sales | $ | 545.8 | $ | 525.0 | 4% | ||||||||||||||||||||||||||||||||||||
| International sales | 400.7 | 393.5 | 2% | ||||||||||||||||||||||||||||||||||||||
| Net sales | $ | 946.5 | $ | 918.5 | 3% | 2% | —% | 1% | 3% | ||||||||||||||||||||||||||||||||
| Adjusted EBITDA | 320.0 | 310.8 | 3% | 2% | —% | 1% | 3% | ||||||||||||||||||||||||||||||||||
| Adjusted EBITDA margin | 33.8 | % | 33.8 | % | — bps | — bps | — bps | — bps | — bps |
-
Organic sales for the three and nine months ended September 30, 2026 reflect positive price. Higher volumes in the Company’s businesses serving municipal water and semiconductor markets were partially offset by lower volumes in the Company’s businesses serving the chemical, energy and agriculture markets.
-
Adjusted EBITDA margin for the three months ended September 30, 2026 increased slightly due to net productivity improvements and volume leverage, mostly offset by unfavorable mix and higher variable compensation. Adjusted EBITDA margin for the nine months ended September 30, 2026 was flat. Net productivity improvements were offset by unfavorable mix.
Fire & Safety/Diversified Products Segment
| Three Months Ended September 30, | Components of Change | ||||||||||||||||||||||||||||||||||||||||
| (In millions) | 2026 | 2025 | Change | Organic | Acq/Div | Foreign Currency | Total | ||||||||||||||||||||||||||||||||||
| Domestic sales | $ | 102.9 | $ | 94.6 | 9% | ||||||||||||||||||||||||||||||||||||
| International sales | 88.6 | 87.3 | 1% | ||||||||||||||||||||||||||||||||||||||
| Net sales | $ | 191.5 | $ | 181.9 | 5% | 6% | —% | (1%) | 5% | ||||||||||||||||||||||||||||||||
| Adjusted EBITDA | 54.5 | 49.3 | 11% | 12% | —% | (1%) | 11% | ||||||||||||||||||||||||||||||||||
| Adjusted EBITDA margin | 28.5 | % | 27.1 | % | 140 bps | 150 bps | — bps | (10) bps | 140 bps |
| Nine Months Ended September 30, | Components of Change | ||||||||||||||||||||||||||||||||||||||||
| (In millions) | 2026 | 2025 | Change | Organic | Acq/Div | Foreign Currency | Total | ||||||||||||||||||||||||||||||||||
| Domestic sales | $ | 296.0 | $ | 283.9 | 4% | ||||||||||||||||||||||||||||||||||||
| International sales | 273.7 | 273.8 | —% | ||||||||||||||||||||||||||||||||||||||
| Net sales | $ | 569.7 | $ | 557.7 | 2% | 1% | —% | 1% | 2% | ||||||||||||||||||||||||||||||||
| Adjusted EBITDA | 165.2 | 159.9 | 3% | 3% | —% | —% | 3% | ||||||||||||||||||||||||||||||||||
| Adjusted EBITDA margin | 29.0 | % | 28.7 | % | 30 bps | 30 bps | — bps | — bps | 30 bps |
- Organic sales for the three and nine months ended September 30, 2026 reflect positive price as well as higher volumes in the Company’s BAND-IT and Fire & Safety businesses driven by strong aerospace and North America fire original
equipment manufacturers (“OEMs”) demand, respectively, which were offset by lower volumes in the Company’s Dispensing businesses in the nine months ended September 30, 2026.
- Adjusted EBITDA margin increased for the three and nine months ended September 30, 2026 primarily due to net productivity improvements partially offset by price/cost headwinds. Adjusted EBITDA margin for the three months ended September 30, 2026 also benefited from volume leverage and favorable mix, while Adjusted EBITDA margin for the nine months ended September 30, 2026 was negatively impacted by unfavorable mix.
Liquidity and Capital Resources
Liquidity
Based on management’s current expectations and currently available information, the Company believes current cash, cash from operations and cash available under the Revolving Facility will be sufficient to meet its cash requirements, including funding of working capital, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements, share repurchases and quarterly dividend payments to holders of the Company’s common stock for the foreseeable future. Additionally, in the event that suitable businesses are available for acquisition upon acceptable terms, the Company may obtain all or a portion of the financing for these acquisitions through the incurrence of additional borrowings. The Company believes that additional borrowings through various financing alternatives remain available, if required.
Select key liquidity metrics at September 30, 2026 are as follows:
| (In millions) | September 30, 2026 | |||||||
| Working capital | $ | 1,130.6 | ||||||
| Current ratio | 2.8 to 1 | |||||||
| Cash and cash equivalents | $ | 602.1 | ||||||
| Cash held outside of the United States | 541.9 | |||||||
| Revolving Facility capacity | $ | 800.0 | ||||||
| Borrowings | 158.5 | |||||||
| Letters of credit | 3.8 | |||||||
| Revolving Facility availability | $ | 637.7 |
Operating Working Capital
Operating working capital, calculated as Receivables – net plus Inventories – net minus Trade accounts payable, is used by management as a measurement of operational results as well as the short-term liquidity of the Company. The following table details Operating working capital as of September 30, 2026 and December 31, 2025:
| (In millions) | September 30, 2026 | December 31, 2025 | Change | Organic Change | ||||||||||||||||||||||
| Receivables – net | $ | 548.6 | $ | 521.7 | $ | 26.9 | $ | 32.6 | ||||||||||||||||||
| Inventories – net | 529.1 | 479.4 | 49.7 | 55.7 | ||||||||||||||||||||||
| Less: Trade accounts payable | 238.3 | 224.7 | 13.6 | 16.1 | ||||||||||||||||||||||
| Operating working capital | $ | 839.4 | $ | 776.4 | $ | 63.0 | $ | 72.2 |
Acquisitions and foreign currency translation decreased Operating working capital by $9.2 million during the nine months ended September 30, 2026. Apart from these items, the primary drivers of the change in Operating working capital were higher sales volumes and positive price leading to higher receivables and higher inventories, which increased to support planned production.
Cash Flow Summary
The following table is derived from the Condensed Consolidated Statements of Cash Flows:
| Nine Months Ended September 30, | ||||||||||||||||||||
| (In millions) | 2026 | 2025 | Change | |||||||||||||||||
| Net cash flows provided by (used in): | ||||||||||||||||||||
| Operating activities | $ | 543.2 | $ | 470.9 | $ | 72.3 | ||||||||||||||
| Investing activities | (67.7) | (120.0) | 52.3 | |||||||||||||||||
| Financing activities | (441.4) | (424.9) | (16.5) |
Operating Activities
Cash provided by operating activities increased $72.3 million in the nine months ended September 30, 2026 as compared to the prior year period. Improved operational results and the net benefit of cash received for IEEPA tariff refunds were partially offset by higher cash tax payments.
Investing Activities
Cash used in investing activities decreased $52.3 million in the nine months ended September 30, 2026 as compared to the prior year period primarily due to the purchase of Micro-LAM during the nine months ended September 30, 2025 for $80.7 million, partially offset by a $22.0 million increase in capital expenditures and the absence of $4.2 million of funds received in connection with the finalization of the Mott purchase price in the prior year period.
Financing Activities
Cash used in financing activities increased $16.5 million in the nine months ended September 30, 2026 as compared to the prior year period. The nine months ended September 30, 2026 included $77.1 million of higher net payments under the Revolving Facility and $53.0 million of higher share repurchases, partially offset by $16.9 million of higher proceeds from stock option exercises, net of shares withheld for taxes. The nine months ended September 30, 2025 also included a $100.0 million payment on long-term borrowings that did not reoccur in the current year period.
Free Cash Flow
The Company believes free cash flow, a non-GAAP measure, is an important measure of performance because it provides a measurement of cash generated from operations that is available for payment obligations such as operating cash requirements, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements and quarterly dividend payments to holders of the Company’s common stock as well as for funding acquisitions and share repurchases. Free cash flow is calculated as cash flows provided by operating activities less capital expenditures.
The following table reconciles cash flows provided by operating activities to free cash flow:
| Nine Months Ended September 30, | ||||||||||||||
| (In millions) | 2026 | 2025 | ||||||||||||
| Cash flows provided by operating activities | $ | 543.2 | $ | 470.9 | ||||||||||
| Less: capital expenditures | 65.9 | 43.9 | ||||||||||||
| Free cash flow | $ | 477.3 | $ | 427.0 | ||||||||||
Cash Requirements
Subsequent Share Repurchases
Subsequent to September 30, 2026, the Company repurchased 0.1 million shares at a cost of $20.5 million.
Capital Expenditures
Capital expenditures generally include machinery and equipment that support growth and improved productivity, tooling, business system technology, replacement of equipment and investments in new facilities. The Company believes it has sufficient operating cash flows to continue to meet current obligations and invest in planned capital expenditures. Cash flows from operations were more than adequate to fund capital expenditures of $65.9 million and $43.9 million in the first nine months of 2026 and 2025, respectively.
Share Repurchases
During the nine months ended September 30, 2026, the Company paid $228.0 million for share repurchases, comprised of $223.5 million for shares repurchased and settled during the period, $2.2 million for shares repurchased in December 2025 that settled in January 2026 and $2.3 million of excise taxes for shares repurchased in 2025. During the nine months ended September 30, 2025, the Company paid $175.0 million for shares repurchased and settled during the period. As of September 30, 2026, the amount of share repurchase authorization remaining was $699.7 million, excluding fees, commissions, excise taxes and other expenses related to such common stock repurchases. For additional information regarding the Company’s share repurchase program, refer to Note 11, “Share Repurchases,” in the Notes to Condensed Consolidated Financial Statements.
Dividends
Total dividend payments to common shareholders were $160.7 million during the nine months ended September 30, 2026 compared with $159.4 million during the nine months ended September 30, 2025.
Covenants
At September 30, 2026, the Company was in compliance with the covenants contained in the credit agreement associated with the Revolving Facility as well as other long-term debt agreements. The key financial covenants that the Company is required to maintain in connection with the 5.13% Senior Notes are a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.50 to 1, which is the ratio of the Company’s consolidated total debt to its consolidated EBITDA, as defined within the Credit Agreement. The key financial covenant the Company is required to maintain in connection with the Revolving Facility is a net leverage ratio of 3.50 to 1, which is the ratio of the Company’s consolidated total debt less eligible cash deductions to its consolidated EBITDA, as defined within the Credit Agreement. At September 30, 2026, the Company’s interest coverage ratio was 14.69 to 1 for covenant calculation purposes, the leverage ratio was 1.72 to 1 and the net leverage ratio was 1.39 to 1. There are no financial covenants relating to the 2.625% Senior Notes, the 3.00% Senior Notes or the 4.950% Senior Notes; however, all are subject to cross-acceleration provisions.
Credit Ratings
The Company’s credit ratings, which were independently developed by the following credit agencies, are detailed below:
-
S&P Global Ratings reaffirmed the Company’s corporate credit rating of BBB (stable outlook) in September 2024.
-
Moody’s Investors Service affirmed the Company’s corporate credit rating of Baa2 (stable outlook) in August 2024.
-
Fitch Ratings affirmed the Company’s corporate credit rating of BBB+ (stable outlook) in September 2026.
Off-Balance Sheet Arrangements
The Company had $24.6 million of letters of credit as of September 30, 2026, primarily issued as security for insurance and other performance obligations. Of the $24.6 million of letters of credit, only $3.8 million reduced the Company’s borrowing capacity under the Revolving Facility as of September 30, 2026.
Except as disclosed above, the Company has no off-balance sheet arrangements that currently have or are reasonably likely to have a material effect on the Company’s consolidated financial condition, changes in financial condition, results of operations, liquidity, capital expenditures or capital resources.
Critical Accounting Estimates
There have been no changes to the Company’s critical accounting estimates described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Non-GAAP Disclosures
The Company prepares its financial statements in accordance with U.S. GAAP. To supplement its U.S. GAAP financial results, the Company presents certain non-GAAP financial measures. Management uses these non-GAAP measures to evaluate operating performance, assess trends, allocate resources and support financial and operational decision-making. Management believes these measures provide investors with additional insight into the Company’s ongoing business performance and enhance comparability across reporting periods by excluding the impact of items that management does not consider reflective of ongoing operations.
Management uses Adjusted EBITDA as its measure of segment performance. Management believes it is a useful indicator of the strength and performance of the Company and its segments’ ongoing business operations as well as a way for investors to evaluate and compare operating performance and value companies within the Company’s industry. Management believes that Adjusted EBITDA margin is useful for the same reasons as Adjusted EBITDA. The definition of Adjusted EBITDA used here may differ from that used by other companies.
The Company defines its non-GAAP measures below and presents reconciliations of these non-GAAP measures to their most directly comparable U.S. GAAP measures in the tables that follow. There were no adjustments to U.S. GAAP financial performance metrics other than the items noted below.
-
Organic sales are calculated as Net sales excluding amounts from acquired or divested businesses during the first twelve months of ownership or prior to divestiture and excluding the impact of foreign currency translation.
-
Adjusted gross profit is calculated as Gross profit, adjusted to exclude the impact of fair value inventory step-up charges and restructuring-related charges.
-
Adjusted gross margin is calculated as Adjusted gross profit divided by Net sales.
-
Adjusted net income attributable to IDEX is calculated as Net income attributable to IDEX, adjusted to exclude the impact of fair value inventory step-up charges, Restructuring expenses and asset impairments and other restructuring-related charges, acquisition-related intangible asset amortization and legal settlements and contingencies, all net of the statutory tax expense or benefit.
-
Adjusted diluted EPS attributable to IDEX is calculated as Adjusted net income attributable to IDEX divided by the diluted weighted average shares outstanding.
-
Consolidated Adjusted EBITDA is calculated as consolidated earnings before interest expense - net, income taxes, depreciation and amortization, or consolidated EBITDA, adjusted to exclude the impact of fair value inventory step-up charges, Restructuring expenses and asset impairments and other restructuring-related charges and legal settlements and contingencies.
-
Consolidated Adjusted EBITDA margin is calculated as Consolidated Adjusted EBITDA divided by Net sales.
-
Free cash flow is calculated as cash flows from operating activities less capital expenditures. This non-GAAP measure is discussed and reconciled to its most directly comparable U.S. GAAP measure in the section above titled “Free Cash Flow.”
These non-GAAP financial measures should be considered in addition to, and not as a substitute for or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from those results should be carefully evaluated. Due to rounding, numbers presented throughout this and other documents may not add up or recalculate precisely.
| Table 1. Reconciliations of the Change in Net Sales to Change in Organic Sales | |||||||||||||||||||||||
| HST | FMT | FSDP | IDEX | ||||||||||||||||||||
| Three Months Ended September 30, 2026 | |||||||||||||||||||||||
| Change in net sales | 14 | % | 3 | % | 5 | % | 8 | % | |||||||||||||||
| Less: | |||||||||||||||||||||||
| Net impact from acquisitions/divestitures(1) | 1 | % | — | % | — | % | — | % | |||||||||||||||
| Impact from foreign currency(2) | — | % | (1 | %) | (1 | %) | — | % | |||||||||||||||
| Change in organic sales | 13 | % | 4 | % | 6 | % | 8 | % | |||||||||||||||
| Nine Months Ended September 30, 2026 | |||||||||||||||||||||||
| Change in net sales | 15 | % | 3 | % | 2 | % | 8 | % | |||||||||||||||
| Less: | |||||||||||||||||||||||
| Net impact from acquisitions/divestitures(1) | 2 | % | — | % | — | % | 1 | % | |||||||||||||||
| Impact from foreign currency(2) | 1 | % | 1 | % | 1 | % | 1 | % | |||||||||||||||
| Change in organic sales | 12 | % | 2 | % | 1 | % | 6 | % |
(1) Represents the sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture.
(2) The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales, and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period.
| Table 2. Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (in millions) | |||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Gross profit | $ | 429.5 | $ | 390.6 | $ | 1,254.4 | $ | 1,151.7 | |||||||||||||||
| Fair value inventory step-up charges | — | 0.6 | — | 0.6 | |||||||||||||||||||
| Restructuring-related charges(1) | 0.8 | — | 1.3 | — | |||||||||||||||||||
| Adjusted gross profit | $ | 430.3 | $ | 391.2 | $ | 1,255.7 | $ | 1,152.3 | |||||||||||||||
| Net sales | $ | 951.7 | $ | 878.7 | $ | 2,759.2 | $ | 2,558.4 | |||||||||||||||
| Gross margin | 45.1 | % | 44.5 | % | 45.5 | % | 45.0 | % | |||||||||||||||
| Adjusted gross margin | 45.2 | % | 44.5 | % | 45.5 | % | 45.0 | % |
(1) Restructuring-related charges represent costs incurred related to the anticipated closure of a facility in the HST segment, including accelerated depreciation of $0.7 million and $1.2 million during the three and nine months ended September 30, 2026, respectively.
| Table 3. Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except for per share amounts) | |||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Reported net income attributable to IDEX | $ | 144.1 | $ | 127.8 | $ | 407.5 | $ | 354.9 | |||||||||||||||
| Fair value inventory step-up charges | — | 0.6 | — | 0.6 | |||||||||||||||||||
| Tax impact on fair value inventory step-up charges | — | (0.1) | — | (0.1) | |||||||||||||||||||
| Restructuring expenses and asset impairments and other restructuring-related charges(1) | 4.2 | 0.1 | 14.9 | 18.0 | |||||||||||||||||||
| Tax impact on restructuring expenses and asset impairments and other restructuring-related charges | (0.9) | (0.1) | (3.4) | (4.4) | |||||||||||||||||||
| Legal settlements and contingencies(2) | (0.2) | — | (3.0) | — | |||||||||||||||||||
| Tax impact on legal settlements and contingencies | 0.7 | — | 1.8 | — | |||||||||||||||||||
| Acquisition-related intangible asset amortization | 32.6 | 33.0 | 99.6 | 96.5 | |||||||||||||||||||
| Tax impact on acquisition-related intangible asset amortization | (7.7) | (8.5) | (23.6) | (23.2) | |||||||||||||||||||
| Adjusted net income attributable to IDEX | $ | 172.8 | $ | 152.8 | $ | 493.8 | $ | 442.3 | |||||||||||||||
| Reported diluted EPS attributable to IDEX | $ | 1.95 | $ | 1.70 | $ | 5.49 | $ | 4.70 | |||||||||||||||
| Fair value inventory step-up charges | — | 0.01 | — | 0.01 | |||||||||||||||||||
| Tax impact on fair value inventory step-up charges | — | — | — | — | |||||||||||||||||||
| Restructuring expenses and asset impairments and other restructuring-related charges(1) | 0.06 | — | 0.20 | 0.24 | |||||||||||||||||||
| Tax impact on restructuring expenses and asset impairments and other restructuring-related charges | (0.01) | — | (0.04) | (0.06) | |||||||||||||||||||
| Legal settlements and contingencies(2) | — | — | (0.04) | — | |||||||||||||||||||
| Tax impact on legal settlements and contingencies | 0.01 | — | 0.02 | — | |||||||||||||||||||
| Acquisition-related intangible asset amortization | 0.42 | 0.43 | 1.34 | 1.27 | |||||||||||||||||||
| Tax impact on acquisition-related intangible asset amortization | (0.10) | (0.11) | (0.32) | (0.31) | |||||||||||||||||||
| Adjusted diluted EPS attributable to IDEX | $ | 2.33 | $ | 2.03 | $ | 6.65 | $ | 5.85 | |||||||||||||||
| Diluted weighted average shares outstanding | 74.0 | 75.2 | 74.2 | 75.5 |
(1) Restructuring expenses and asset impairments and other restructuring-related charges consist of the following:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Restructuring expenses and asset impairments | $ | 3.4 | $ | 0.1 | $ | 13.6 | $ | 18.3 | |||||||||||||||
| Less: Restructuring expenses and asset impairments attributable to noncontrolling interest(a) | — | — | — | (0.3) | |||||||||||||||||||
| Other restructuring-related charges(b) | 0.8 | — | 1.3 | — | |||||||||||||||||||
| Restructuring expenses and asset impairments and other restructuring-related charges | $ | 4.2 | $ | 0.1 | $ | 14.9 | $ | 18.0 |
(a) Restructuring expenses and asset impairments recorded during the nine months ended September 30, 2025 included charges of $0.6 million recognized by the Company’s joint venture, $0.3 million of which was attributable to noncontrolling interest.
(b) Other restructuring-related charges represent costs incurred related to the anticipated closure of a facility in the HST segment, including accelerated depreciation of $0.7 million and $1.2 million during the three and nine months ended September 30, 2026, respectively.
(2) Legal settlements and contingencies include legal settlement funds received, net of associated legal costs incurred.
| Table 4. Reconciliations of Net Income to Adjusted EBITDA (in millions) | |||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Reported net income | $ | 144.0 | $ | 127.7 | $ | 407.3 | $ | 354.2 | |||||||||||||||
| Provision for income taxes | 48.7 | 42.8 | 128.5 | 110.7 | |||||||||||||||||||
| Interest expense – net | 15.4 | 16.5 | 46.5 | 48.2 | |||||||||||||||||||
| Depreciation(1) | 20.8 | 19.1 | 60.9 | 56.5 | |||||||||||||||||||
| Amortization | 32.6 | 33.0 | 99.6 | 96.5 | |||||||||||||||||||
| Fair value inventory step-up charges | — | 0.6 | — | 0.6 | |||||||||||||||||||
| Restructuring expenses and asset impairments and other restructuring-related charges(1) | 3.5 | 0.1 | 13.7 | 18.3 | |||||||||||||||||||
| Legal settlements and contingencies(2) | (0.2) | — | (3.0) | — | |||||||||||||||||||
| Adjusted EBITDA | $ | 264.8 | $ | 239.8 | $ | 753.5 | $ | 685.0 | |||||||||||||||
| Adjusted EBITDA Components | |||||||||||||||||||||||
| HST | $ | 124.8 | $ | 105.4 | $ | 350.1 | $ | 287.8 | |||||||||||||||
| FMT | 111.0 | 106.8 | 320.0 | 310.8 | |||||||||||||||||||
| FSDP | 54.5 | 49.3 | 165.2 | 159.9 | |||||||||||||||||||
| Corporate and other | (25.5) | (21.7) | (81.8) | (73.5) | |||||||||||||||||||
| Total Adjusted EBITDA | $ | 264.8 | $ | 239.8 | $ | 753.5 | $ | 685.0 | |||||||||||||||
| Net sales | $ | 951.7 | $ | 878.7 | $ | 2,759.2 | $ | 2,558.4 | |||||||||||||||
| Net income margin | 15.1 | % | 14.5 | % | 14.8 | % | 13.8 | % | |||||||||||||||
| Adjusted EBITDA margin | 27.8 | % | 27.3 | % | 27.3 | % | 26.8 | % |
(1) Accelerated depreciation of $0.7 million and $1.2 million for the three and nine months ended September 30, 2026, respectively, related to the anticipated closure of a facility in the HST segment, was included in Depreciation in Table 4, in Restructuring-related charges in Table 2 and in Restructuring expenses and asset impairments and other restructuring-related charges in Table 3 above.
(2) Legal settlements and contingencies include legal settlement funds received, net of associated legal costs incurred.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes with respect to market risks disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Item 4. Controls and Procedures
The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
As required by SEC Rule 13a-15(b), the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2026.
There has been no change in the Company’s internal control over financial reporting during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
The Company and its subsidiaries are party to legal proceedings incidental to the operation of their businesses as described in Note 14 in Part I, Item 1, “Commitments and Contingencies,” in the Notes to Condensed Consolidated Financial Statements and such disclosure is incorporated by reference into this Item 1. “Legal Proceedings.”
The Company’s threshold for disclosing material environmental legal proceedings involving a government authority where potential monetary sanctions are involved is $1.0 million.
In addition, the Company and eight of its subsidiaries are presently named as defendants in a number of lawsuits claiming various asbestos-related personal injuries, allegedly as a result of exposure to products manufactured with components that contained asbestos. These components were acquired from third-party suppliers and were not manufactured by the Company or any of the defendant subsidiaries. To date, the majority of the Company’s settlements and legal costs, except for costs of coordination, administration, insurance investigation and a portion of defense costs, have been covered in full by insurance, subject to applicable deductibles. However, the Company cannot predict whether and to what extent insurance will be available to continue to cover these settlements and legal costs, or how insurers may respond to claims that are tendered to them. Asbestos-related claims have been filed in jurisdictions throughout the United States and the United Kingdom. Most of the claims resolved to date have been dismissed without payment. The balance of the claims has been settled for various immaterial amounts. Only one case has been tried, resulting in a verdict for the Company’s business unit. No provision has been made in the financial statements of the Company, other than for insurance deductibles in the ordinary course, and the Company does not currently believe the asbestos-related claims will have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.
Item 1A. Risk Factors
There have been no material changes with respect to risk factors disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information about the Company’s purchases of its common stock during the quarter ended September 30, 2026:
| Period | Total Number of Shares Purchased | Average Price Paid per Share**(1)** | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value that May Yet be Purchased Under the Plans or Programs**(2)** | |||||||||||||||||||
| July 1, 2026 to July 31, 2026 | 113,528 | $ | 224.18 | 113,528 | $ | 749,239,070 | |||||||||||||||||
| August 1, 2026 to August 31, 2026 | 105,463 | 234.79 | 105,463 | 724,477,001 | |||||||||||||||||||
| September 1, 2026 to September 30, 2026 | 110,044 | 225.25 | 110,044 | 699,689,773 | |||||||||||||||||||
| Total | 329,035 | $ | 227.94 | 329,035 | $ | 699,689,773 |
(1)Excludes commissions and the 1% excise tax imposed by the Inflation Reduction Act of 2022.
(2)On September 17, 2025, the Company’s Board of Directors authorized the repurchase of an additional $635.0 million of the Company’s common shares. This approval is in addition to the prior repurchase authorization of the Company’s Board of Directors of $500.0 million on March 17, 2020. These authorizations have no expiration date and exclude fees, commissions, excise taxes and other expenses related to such common stock repurchases.
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the quarter ended September 30, 2026, none of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended.
Item 6. Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| IDEX Corporation | ||||||||
| By: | /s/ SEAN M. GILLEN | |||||||
| Sean M. Gillen | ||||||||
| Senior Vice President and Chief Financial Officer |
Date: October 28, 2026